Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial
Komal Jhaveri, Hope S. Rugo, Javier Cortés, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Henry L. Gomez, Xichun Hu, Petr Krivorotko, Sibylle Loibl, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Lyudmila Zhukova, Agostina Nardone, Ian Wadsworth, Celina D’Cruz, Tanya Wantenaar, Dimple Das, Elza C. de Bruin, Nicholas C. Turner · 2026
Read Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial by Komal Jhaveri, Hope S. Rugo, Javier Cortés, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Henry L. Gomez, Xichun Hu, Petr Krivorotko, Sibylle Loibl, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Lyudmila Zhukova, Agostina Nardone, Ian Wadsworth, Celina D’Cruz, Tanya Wantenaar, Dimple Das, Elza C. de Bruin, Nicholas C. Turner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473863.txt.
Description
Jhaveri and colleagues tested in 2026 whether a tissue stain can stand in for gene sequencing to find PTEN-deficient breast tumors in the phase III CAPItello-291 trial. Loss of PTEN, a brake on a growth pathway, helps select patients for the AKT blocker capivasertib plus fulvestrant, but sequencing is the usual route. The team ran the stain, called immunohistochemistry, on 367 tumor samples and compared it with sequencing results.
About one in five samples stained as PTEN deficient. Against sequencing, the stain agreed in 87 percent of cases overall, catching about seven in ten sequencing-positive tumors and clearing nearly nine in ten negative ones. Among stain-positive patients, those on the drug pair lived a median of just over nine months without progression against under four months on the control pairing. The authors say staining may widen access to the treatment by flagging extra patients who could benefit.
Catalog record
| CREATOR | Komal Jhaveri, Hope S. Rugo, Javier Cortés, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Henry L. Gomez, Xichun Hu, Petr Krivorotko, Sibylle Loibl, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Lyudmila Zhukova, Agostina Nardone, Ian Wadsworth, Celina D’Cruz, Tanya Wantenaar, Dimple Das, Elza C. de Bruin, Nicholas C. Turner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |